research Fulvestrant: A New Treatment Option for Advanced Breast Cancer - Tolerability Versus Existing Agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
Search
for
Sort by
Research
11 / 11 results 
research Estrogen Receptor Antagonist and Hair Regrowth in Dogs with Hair Cycle Arrest (Alopecia X)
Fulvestrant at 10 mg/kg does not promote hair regrowth in dogs with alopecia X.
research Onychomatricoma with Classic Features: Case Report and Review of the Literature
Hair loss is a common side effect of hormone treatments for cancer.
research Revising the Role of the Androgen Receptor in Breast Cancer
The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
research Effect of Estrogens on Skin Aging and the Potential Role of Selective Estrogen Receptor Modulators
Estrogens and SERMs can help with skin aging, but their safety and effectiveness need more research.
research Experimental and Early Investigational Drugs for Androgenetic Alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
research Drug Safety Evaluation of Exemestane
Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
research Steroid Hormones of Reproduction and Sexual Development
Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.
research Hormone Blocking Anticancer Drugs
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
research Hair Cycle and Alopecia X in Dogs
Alopecia X in dogs is a cosmetic issue, not a hormonal disorder, and harmful treatments should be avoided.
research Safety of 5α-Reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies
The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.